{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/otitis-media-acute/management/acute-otitis-media-initial-presentation/","result":{"pageContext":{"chapter":{"id":"35db78a7-148c-5b20-8fd7-54ea5aaba599","slug":"acute-otitis-media-initial-presentation","fullItemName":"Scenario: Acute otitis media - initial presentation","depth":2,"htmlHeader":"<!-- begin field b3433530-1fd3-42e6-85ca-6f2a642395f7 --><h2>Scenario: Acute otitis media - initial presentation</h2><!-- end field b3433530-1fd3-42e6-85ca-6f2a642395f7 -->","summary":"Covers the management of people presenting to primary care for the first time with an episode of acute otitis media (AOM).","htmlStringContent":"<!-- begin item f84a110b-2f3d-486f-a4d5-9246db95bdf8 --><!-- begin field 7b7bc5c2-cb39-4062-8464-acbd008521de --><p>From age 1 month onwards.</p><!-- end field 7b7bc5c2-cb39-4062-8464-acbd008521de --><!-- end item f84a110b-2f3d-486f-a4d5-9246db95bdf8 -->","topic":{"id":"0671aacb-4e00-5bb2-8b54-aa0da27fb4ab","topicId":"009f13e7-d649-401b-8b63-061c029e67f2","topicName":"Otitis media - acute","slug":"otitis-media-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"793c7288-db92-5c67-8ef6-0ea9a20f6b09","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0cbb536b-178c-5bea-a1c6-22c584a7e1b6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"944570b9-0a8f-5b67-8ee8-556c3fd8a613","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"aedad1bf-9c58-57d9-9c3d-d1fa6e40ee13","slug":"changes","fullItemName":"Changes"},{"id":"7bc4152c-a9f8-5afe-bb63-2a48a86ebf0d","slug":"update","fullItemName":"Update"}]},{"id":"cd84410b-569d-58a4-8fe8-c2eaed2ead26","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7875d022-7cbf-5961-a19e-d5987af92edc","slug":"goals","fullItemName":"Goals"},{"id":"8db5ac64-8db5-5daa-aa3c-d46caaf0abf3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3517d1cc-7aae-5036-81f5-ac0b590e84fd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4ca0ace8-77fc-5319-95e0-e983fa092ed9","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f87cf2b3-b0ea-5485-b424-9518a3f586a2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e285c16b-d4ba-56b6-a3fd-3c27fc822357","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"749e39ba-56ce-5129-8e10-fef140b586c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9df3117d-949e-56bb-ac40-0393fb87071a","slug":"definition","fullItemName":"Definition"},{"id":"cb42b641-fdc3-5bd6-a13a-ca2c1edd9c21","slug":"causes","fullItemName":"Causes"},{"id":"2682b3f3-3099-54c9-9c02-867b7f3350e0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a7d4a184-6baa-5ae6-baef-11eba15038e6","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"fc412f0f-261f-5fae-a125-cfeefdd5e8b3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"18e296ab-cfe3-58be-bf23-aaf4a6c6f49e","slug":"complications","fullItemName":"Complications"}]},{"id":"a0da1ac3-73ef-561b-9301-a1ccdf5fd8a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9e9b0e14-9f7d-5c5a-83a1-c4bfd193ba3d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"7e76e099-c70a-5f57-b670-c0ad43913066","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0dac3638-3899-5899-bd0e-647894c3f003","fullItemName":"Management","slug":"management","subChapters":[{"id":"35db78a7-148c-5b20-8fd7-54ea5aaba599","slug":"acute-otitis-media-initial-presentation","fullItemName":"Scenario: Acute otitis media - initial presentation"},{"id":"4d27de1d-1fe0-5438-98c0-f85415825ca5","slug":"persistent-acute-otitis-media-treatment-failure","fullItemName":"Scenario: Persistent acute otitis media - treatment failure"},{"id":"7d848f0c-bb0a-5ea7-90f2-dd99a1cbc49e","slug":"recurrent-acute-otitis-media","fullItemName":"Scenario: Recurrent acute otitis media"}]},{"id":"c8285b67-3320-54ae-8537-4c0626e3632e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f512abb6-f15e-5fef-9f9d-23e008c401ff","slug":"analgesia","fullItemName":"Analgesia"},{"id":"15d20ee0-531c-5230-9e41-6194bfbe3614","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"859385d7-8fde-5b5e-8357-c34d3500eeb7","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"bb1b0220-4609-5ab7-8102-e31414c36dab","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"0f55a4d8-b11d-53a6-a26e-b2a9e98e8dd8","slug":"erythromycin","fullItemName":"Erythromycin"}]},{"id":"f43bc1b4-a67e-5bab-b27c-d141e7483b01","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"51596c5b-15a7-547d-bdcf-f7a467961cd7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f91fb8f9-4942-5683-8b3d-d8edd775f700","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c2fdf612-fff8-581e-bf78-7c9efcf08ddf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2bb0e3c7-8948-5401-97a7-741ffa1d4477","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"570abb9c-faad-515e-86bb-0b947414dcb9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5e5c540f-ce64-5768-9c46-dfde85f5364a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7f9af8df-6314-54fa-a769-b5bd0bd121ab","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0dac3638-3899-5899-bd0e-647894c3f003","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"1ce88c67-389f-56bd-b4e2-faea14a98369","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field c2fdedb4-021e-478c-85e5-a74c00b9c401 --><h3>How should I manage people at initial presentation?</h3><!-- end field c2fdedb4-021e-478c-85e5-a74c00b9c401 -->","summary":null,"htmlStringContent":"<!-- begin item c219e821-7f20-4334-91f0-a74c00b9c358 --><!-- begin field 1d54b7e3-b580-4828-ba60-a74c00b9c401 --><ul><li><strong>Admit for immediate specialist assessment: </strong><ul><li>People with a severe systemic infection.</li><li>People with suspected acute <a class=\"topic-reference internal-reference\" href=\"/topics/otitis-media-acute/background-information/complications/\">complications</a> of acute otitis media (AOM), such as meningitis, mastoiditis, intracranial abscess, sinus thrombosis, or facial nerve paralysis.</li><li>Children younger than 3 months of age with a temperature of 38°C or more. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/feverish-children-risk-assessment/\">Feverish children - risk assessment</a> for more information. </li></ul></li><li><strong>Consider admitting:</strong><ul><li>Children younger than 3 months of age. </li><li>Children 3–6 months of age with a temperature of 39°C or more.</li></ul></li><li><strong>For all people with AOM:</strong><ul><li>Advise that the usual course of acute otitis media is about 3 days, but can be up to 1 week. </li><li>Advise regular doses of paracetamol or ibuprofen for pain, using a dosing schedule appropriate for the age and weight of a child. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a> and <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>.</li><li>Explain that there is no evidence to support the use of decongestants or antihistamines for the management of symptoms.</li></ul></li><li><strong>For people who do not require admission to hospital but are systemically very unwell, have symptoms and signs of a more serious illness or condition, or have a high risk of complications</strong><strong>:</strong><ul><li>Offer an immediate antibiotic prescription. </li><li>Advise them to seek medical advice if symptoms worsen rapidly or significantly or they become systemically very unwell.</li></ul></li><li><strong>For people who may be more likely to benefit from antibiotics (those with otorrhoea, or those aged less than 2 years with bilateral infection), </strong>take account of evidence that acute complications such as mastoiditis are rare with or without antibiotics, and the possible adverse effects of antibiotics and consider:<ul><li><strong>No antibiotic prescription</strong> — with advice about an antibiotic not being needed and seeking medical help if symptoms worsen rapidly or significantly, do not improve after 3 days, or the person becomes systemically very unwell, or</li><li><strong>A back-up antibiotic prescription</strong> — with advice about an antibiotic not being needed immediately; using the back-up prescription if symptoms do not start to improve within 3 days or worsen significantly or rapidly at any time; and seeking medical help if symptoms worsen rapidly or significantly, or the person becomes systemically very unwell, or </li><li><strong>An immediate antibiotic prescription</strong> — with advice to seek medical advice if symptoms worsen rapidly or significantly or the person becomes systemically very unwell. </li></ul></li><li><strong>For other people who may be less likely to benefit from antibiotics,</strong> take into account that antibiotics make little difference to symptoms or the development of common complications (which are rare with or without antibiotics) and possible adverse effects of antibiotics and consider: <ul><li><strong>No antibiotic prescription</strong> — with advice about an antibiotic not being needed and seeking medical help if symptoms worsen rapidly or significantly, do not improve after 3 days, or the person becomes systemically very unwell, or </li><li><strong>A back-up antibiotic prescription</strong> — with advice about an antibiotic not being needed immediately; using the back-up prescription if symptoms do not start to improve within 3 days or worsen significantly or rapidly at any time; and seeking medical help if symptoms worsen rapidly or significantly, or the person becomes systemically very unwell. </li></ul></li><li><strong>If an antibiotic is required: </strong><ul><li>Prescribe a 5–7 day course of amoxicillin.</li><li>For people who are allergic to, or intolerant of, penicillin, prescribe a 5–7 day course of clarithromycin or erythromycin (erythromycin is preferred in pregnant women).<ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/otitis-media-acute/prescribing-information/\">Prescribing information</a> for detailed information on how to prescribe these antibiotics.</li></ul></li></ul></li><li><strong>Reassess at any time if symptoms worsen rapidly or significantly</strong>, taking account of: <ul><li>Alternative diagnoses, such as otitis media with effusion (glue ear). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/otitis-media-with-effusion/\">Otitis media with effusion</a>. </li><li>Any symptoms or signs suggesting a more serious illness or condition. For more information, see the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/otitis-media-acute/background-information/complications/\">Complications</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/otitis-media-acute/diagnosis/differential-diagnosis/\">Differential diagnosis</a>. </li><li>Previous antibiotic use which may lead to resistant organisms.</li></ul></li><li><strong>Routine follow up is not required in the absence of persistent symptoms of AOM.</strong><ul><li>For people with persisting symptoms despite antibiotic treatment, see the <a class=\"topic-reference internal-reference\" href=\"/topics/otitis-media-acute/management/persistent-acute-otitis-media-treatment-failure/\">Scenario: Persistent acute otitis media - treatment failure</a>.</li><li>For people with recurrent symptoms (three or more separate episodes in the previous 6 months, <em>or</em> four or more episodes in the previous 12 months with at least one episode in the past 6 months), see the <a class=\"topic-reference internal-reference\" href=\"/topics/otitis-media-acute/management/recurrent-acute-otitis-media/\">Scenario: Recurrent acute otitis media</a>.</li></ul></li></ul><!-- end field 1d54b7e3-b580-4828-ba60-a74c00b9c401 --><!-- end item c219e821-7f20-4334-91f0-a74c00b9c358 -->","subChapters":[{"id":"9b678b79-fed2-5667-bad7-039ec2a91523","slug":"basis-for-recommendation-070","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 05207227-0418-4625-ab4e-a74c00b9c406 --><h4>Basis for recommendation</h4><!-- end field 05207227-0418-4625-ab4e-a74c00b9c406 -->","summary":null,"htmlStringContent":"<!-- begin item 0707639b-e036-47ab-bdb4-a74c00b9c406 --><!-- begin field 2acd2ec5-5651-49ef-9a4d-a74c00b9c406 --><h5>Criteria for admission</h5><ul><li>The recommendations to immediately admit people with a severe systemic infection or suspected acute complications of otitis media for specialist assessment are based on the NICE guideline <em>Otitis media (acute): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>]. </li><li>The recommendation to admit children younger than 3 months of age with a temperature of 38ºC or more for immediate paediatric assessment is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Feverish illness in children — Assessment and initial management in children younger than 5 years, </em>which places these children in a high-risk group for serious illness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2013</a>]. This is also consistent with advice in the NICE guideline <em>Otitis media (acute): antimicrobial prescribing </em>regarding children with fever [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>]. </li><li>Specific evidence on the most appropriate management of children younger than 3 months of age with suspected AOM is limited.<ul><li>CKS recommends considering admission in this age group on the basis of expert opinion in a US guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">University of Michigan Health System, 2013</a>] which suggests that AOM may be associated with an increased risk of 'a severe or atypical outcome' in infants less than 8 weeks old.</li></ul></li><li>According to the NICE guideline <em>Feverish illness in children — Assessment and initial management in children younger than 5 years</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2013</a>], children aged 3–6 months with a temperature of 39ºC or more are in at least an intermediate risk group for serious illness, so CKS advises using clinical judgement to consider admitting this group.</li></ul><h5>Self care advice for all people with acute otitis media</h5><ul><li>This recommendation is based on the NICE guideline <em>Otitis media (acute): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>]. </li><li>A Cochrane systematic review (search date August 2016) on paracetamol or nonsteroidal anti-inflammatory drugs for pain relief in acute otitis media in children included three randomised controlled trials (n = 327). The Cochrane authors were unable to draw conclusions on the comparative efficacy of paracetamol and ibuprofen due to insufficient available evidence. Low-quality evidence suggested that paracetamol and ibuprofen, when used individually, were more effective than placebo in terms of pain relief at 48 hours [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Sjoukes et al, 2016</a>]:   <ul><li>Paracetamol compared with placebo (n = 148): 10% compared with 25% of children with pain at 48 hours; RR 0.38, 95% CI 0.17 to 0.85.</li><li>Ibuprofen commpared with placebo (n = 146): 7% compared with 25% of children with pain at 48 hours; RR 0.28, 95% CI 0.11 to 0.70.</li><li>The number needed to treat to benefit was calculated as 7 for paracetamol and 6 for ibuprofen.</li><li>Adverse effects were not significantly different between the groups (based on very low-quality evidence), but the sample sizes were small and the adverse effects were infrequent [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>]. </li></ul></li></ul><h5>Immediate antibiotics for people who are systemically unwell, have symptoms and signs of a more serious illness or condition, or are at high risk of complications</h5><ul><li>The recommendation to offer an immediate antibiotic prescription to people who are systemically unwell, have symptoms and signs of a more serious illness or condition, or are at high risk of complications is based on the expert opinion of the NICE committee for the guideline <em>Otitis media (acute): antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>].</li><li>This recommendation is in line with US guidelines and a Canadian position statement on the management of AOM [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Lieberthal et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Le Saux and Robinson, 2016</a>]. </li></ul><h5>Antibiotic prescribing strategies for other groups</h5><ul><li>The recommendations on antibiotic prescribing strategies reflect the expert opinion of the NICE committee for the guideline <em>Otitis media (acute): antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>], taking into account evidence from a Cochrane systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Venekamp et al, 2015</a>]. The committee accepted that most children with acute otitis media require no antibiotic or a back up antibiotic prescription as recommended in the NICE guideline on <em>Respiratory tract infections (self-limiting): prescribing antibiotics</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2008</a>] but that an immediate antibiotic prescription could be considered in children younger than two years of age with bilateral AOM, or of any age with both AOM and ear discharge (based on clinical judgement) because antibiotics were more likely to be beneficial in these groups [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>]. </li><li>The NICE committee noted that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>]:  <ul><li>Both viral and bacterial infections causing acute otitis media are usually self-limiting and do not routinely require antibiotics.</li><li>There is evidence to suggest that antibiotics do not make a significant difference to ear pain, complication rates, or short-term hearing loss.</li><li>Serious complications are rare and the numbers needed to treat with antibiotics to prevent them are very high (around 5000 for mastoiditis).</li></ul></li><li>A Cochrane systematic review (search date April 2015) identified 13 randomized controlled trials (n = 3401, 3938 AOM episodes) of antibiotic treatment for AOM in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Venekamp et al, 2015</a>]. It showed some benefit from antibiotic use for acute otitis media compared with placebo, but the absolute differences in some of the comparisons were small: <ul><li>Of the children in these trials, 60% had recovered 24 hours after starting treatment, regardless of whether they were allocated to antibiotic treatment or placebo.</li><li>Pain was not reduced at 24 hours (risk ratio 0.89, 95% CI 0.78 to 1.01) but improvement in pain was noted at 2–3 days (RR 0.70, 95% CI 0.57 to 0.86; number needed to treat to benefit one person [NNTB] 20), 4–7 days (RR 0.76, 95% CI 0.63 to 0.91; NNTB 16) and 10–12 days (RR 0.33, 95% CI 0.17 to 0.66; NNTB 7) with antibiotics compared with placebo.</li><li>Abnormal tympanometry was reduced at 2–4 weeks (RR 0.82, 95% CI 0.74 to 0.90 NNTB 11) in the antibiotic group compared with placebo.</li><li>Tympanic membrane perforations were reduced in the antibiotic group compared with placebo (RR 0.37, 95% CI 0.18 to 0.76; NNTB 33), as were the numbers of otitis media in the contralateral ear (RR 0.49, 95% CI 0.25 to 0.95; NNTB 11).</li><li>Antibiotics did not reduce the number of children with abnormal tympanometry at 3 months or late AOM recurrences when compared with placebo.</li><li>The most likely groups to benefit from antibiotic treatment were children aged less than 2 years with bilateral AOM (NNTB 4) and children of any age with AOM and otorrhoea (NNTB 3) based on data from six high quality trials (n = 1643).</li><li>For every 14 children treated with antibiotics, one had an adverse event (vomiting, diarrhoea, or rash) that would not have happened if they were not on antibiotics.</li></ul></li><li>A comparison of immediate antibiotics and expectant observation in four trials (n = 1007, moderate quality evidence), found no difference in [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Venekamp et al, 2015</a>]:  <ul><li>Pain between the antibiotic and expectant observation groups at 3–7 days (RR 0.75, 95% CI 0.50 to 1.12) or 11–14 days in a subgroup of 247 children (RR 0.91, 95% CI 0.75 to 1.10).</li><li>Abnormal tympanometry findings at 4 weeks.</li><li>Tympanic membrane perforations.</li><li>Recurrence of acute otitis media.</li></ul></li></ul><h5>Choice of antibiotic and duration of treatment</h5><ul><li>Recommendations on the choice and duration of antibiotic are based on the NICE guideline <em>Otitis media (acute): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>], the PHE publication <em>Management of infection guidance for primary care for consultation and local adaptation </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">PHE, 2017</a>] the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>], and the BNF for Children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF for Children, 2017</a>].  </li><li>NICE reviewed the evidence in a systematic review and meta-analysis and found no major differences between different classes of antibiotics in terms of treatment effectiveness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>].  <ul><li>The NICE committee therefore based the choice of antibiotic on resistance risk, and decided amoxicillin is most appropriate because although phenoxymethylpenicillin is likely to be effective and has a lower risk of resistance, the use of amoxicillin is current practice with an acceptable resistance risk, and it has a more convenient dosing schedule [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>].  </li><li>Clarithromycin and erythromycin are recommended as alternative first-line choices based on the experience of the NICE committee and resistance data. Azithromycin is another option, but this is not recommended because the NICE committee were of the opinion that this should be reserved for more serious infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>]. <strong> </strong></li></ul></li><li>A Cochrane systematic review (search date November 2009) identified 49 trials (n = 12,045) comparing short courses of antibiotics (less than seven days) with long courses (seven days or longer) for the treatment of AOM in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Kozyrskyj et al, 2010</a>]. The review found that compared with short courses, long courses of antibiotics reduced short-term treatment failure (21% treatment failure for short courses compared with 18% for long courses), but had no benefit in the longer term compared with short courses.<ul><li>The NICE committee reviewed this evidence and concluded that a 5–7 day course of antibiotics is appropriate for acute otitis media in children and that the shortest course possible should be prescribed to minimise the risk of resistance, noting the small absolute difference in treatment failure of with antibiotic courses of less than 7 days compared with 7 days or more [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>].  </li></ul></li></ul><h5>Reassessment if symptoms worsen rapidly and significantly</h5><ul><li>This recommendation is based on the NICE guideline <em>Otitis media (acute): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>].</li><li>A Canadian position statement on the management of acute otitis media discusses the importance of evaluation and possible imaging if it is suspected that infection has spread beyond the middle ear (for example, mastoiditis)<strong>. </strong>Other potential complications include acute facial nerve palsy, labyrinthitis, and venous sinus thrombosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Le Saux and Robinson, 2016</a>]. Symptoms such as altered conscious level, vomiting, photophobia, and persistent headache may indicate an intracranial complication (for example, meningitis, or temporal lobe or extradural/subdural abscess) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Atkinson et al, 2015</a>].  </li></ul><h5>Routine follow up not required</h5><ul><li>Routine follow up in the absence of persistent symptoms is not discussed in the NICE guidelines <em>Respiratory tract infections (self-limiting): prescribing antibiotics </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2008</a>] and <em>Otitis media (acute): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>]. The American Academy of Pediatrics guideline on the diagnosis and management of acute otitis media also found limited evidence to support a routine follow up visit for all children with acute otitis media [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Lieberthal et al, 2013</a>]. </li></ul><!-- end field 2acd2ec5-5651-49ef-9a4d-a74c00b9c406 --><!-- end item 0707639b-e036-47ab-bdb4-a74c00b9c406 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}